2-[1-(叔丁氧羰酰)-4-哌啶基]-1,3-噻唑-4-甲酸 | 668484-45-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-[1-(叔丁氧羰酰)-4-哌啶基]-1,3-噻唑-4-甲酸
• 中文别名: 2-[1-(叔丁氧基羰基)-4-哌啶基]-1,3-噻唑-4-羧酸
• 英文名称: 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)thiazole-4-carboxylic acid
• 英文别名: 2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-1,3-thiazole-4-carboxylic acid
• CAS: 668484-45-5
• 化学式: C₁₃H₁₉N₃O₄S
• 分子量: 313.378
• InChiKey: FMSFMUBALWPCQM-UHFFFAOYSA-N

物化性质

• 熔点：
  162 °C
• 沸点：
  0°C
• 密度：
  1.332±0.06 g/cm3(Predicted)
• 闪点：
  0°C

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2934100090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	2-[1-(tert-Butoxycarbonyl)piperid-4-yl]-1 3-thiazole-4-carboxylic Material Safety Data Sheet
Synonym:
CAS:	668484-45-5

Section 1 - Chemical Product MSDS Name:2-[1-(tert-Butoxycarbonyl)piperid-4-yl]-1 3-thiazole-4-carboxylic Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
668484-45-5	2-[1-(tert-Butoxycarbonyl)piperid-4-yl	95+%	unlisted

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Use with adequate ventilation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 668484-45-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Flakes
Color: White
Odor: Without to slight
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 162 - 166 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H20N2O4S
Molecular Weight: 312.39

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong acids, strong bases, strong oxidizing agents, iron salts.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 668484-45-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-[1-(tert-Butoxycarbonyl)piperid-4-yl]-1,3-thiazole-4-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 668484-45-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 668484-45-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 668484-45-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-[1-(叔丁氧羰酰)-4-哌啶基]-1,3-噻唑-4-甲酸 在 吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  SELECTIVE HDAC1,2 INHIBITORS

  摘要：

  本文提供了化合物、含有这些化合物的药物组合物，以及使用这些化合物治疗与HDAC1和/或HDAC2活性相关的疾病或障碍的方法。

  公开号：

  US20180141923A1
• 作为产物：
  描述：

  2-(4-(叔丁氧基羰基)哌嗪-1-基)噻唑-4-羧酸乙酯 在 乙醇 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以94%的产率得到2-[1-(叔丁氧羰酰)-4-哌啶基]-1,3-噻唑-4-甲酸
  参考文献：
  名称：

  SELECTIVE HDAC1,2 INHIBITORS

  摘要：

  本文提供了化合物、含有这些化合物的药物组合物，以及使用这些化合物治疗与HDAC1和/或HDAC2活性相关的疾病或障碍的方法。

  公开号：

  US20180141923A1

文献信息

• NEW COMPOUNDS
  申请人：Proximagen Limited

  公开号：US20150258101A1

  公开（公告）日：2015-09-17

  The present invention provides certain compounds according to formula (I) which are inhibitors of SSAO activity wherein V, W, X, Y, Z, R 1 and R 2 are as defined in the specification.

  本发明提供了一些按照式(I)的化合物，这些化合物是SSAO活性的抑制剂，其中V、W、X、Y、Z、R1和R2如规范中所定义。
• THIAZOLE DERIVATIVES
  申请人：Schiemann Kai

  公开号：US20100240676A1

  公开（公告）日：2010-09-23

  Compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , K, G, E and W

  化学式为（I）的化合物，其中R1，R2，R3，R4，K，G，E和W。
• IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
  申请人：PROXIMAGEN LIMITED

  公开号：US20160046622A1

  公开（公告）日：2016-02-18

  The compounds of formula (I) are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.

  式(I)的化合物是半卡巴肼敏感胺氧化酶（SSAO）活性的抑制剂，可用于治疗炎症、炎症性疾病、免疫或自身免疫性疾病，或抑制肿瘤生长。
• Substituted piperazines as selective HDAC1,2 inhibitors
  申请人：Regenacy Pharmaceuticals, LLC

  公开号：US10385031B2

  公开（公告）日：2019-08-20

  Provided herein are compounds of Formula II, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity

  本文提供了式 II 的化合物、包含此类化合物的药物组合物以及使用此类化合物治疗与 HDAC1 和/或 HDAC2 活性相关的疾病或紊乱的方法
• Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
  申请人：PROXIMAGEN, LLC

  公开号：US10428066B2

  公开（公告）日：2019-10-01

  The compounds of formula (I) are inhibitors of SSAO activity wherein V, W, X, Y, Z, R1 and R2 are as defined in the claims.

  式（I）化合物是 SSAO 活性抑制剂 其中 V、W、X、Y、Z、R1 和 R2 如权利要求中所定义。